Ryder ve 3. čtvrtletí zvýšil tržby meziročně o 8,3 % na 3,43 mld. USD a zisk na akcii (EPS) vzrostl z 3,57 USD na 4,33 USD, čímž společnost překonala odhady analytiků.
For the quarter ended September 2026, Ryder (R - Free Report) reported revenue of $3.43 billion, up 8.3% over the same period last year. EPS came in at $4.33, compared to $3.57 in the year-ago quarter.
The reported revenue represents a surprise of +1.02% over the Zacks Consensus Estimate of $3.4 billion. With the consensus EPS estimate being $4.17, the EPS surprise was +3.84%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ryder performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Average fleet count - ChoiceLease: 140,000 versus 140,217 estimated by two analysts on average.Commercial rental - Rental Utilization - Power Units: 77% versus 75% estimated by two analysts on average.Commercial rental - Average fleet count: 29,400 compared to the 29,701 average estimate based on two analysts.Operating Revenue- Fleet Management Solutions: $1.34 billion compared to the $1.32 billion average estimate based on two analysts. The reported number represents a change of +4.8% year over year.Operating Revenue- Dedicated Transportation Solutions: $455 million compared to the $461.03 million average estimate based on two analysts. The reported number represents a change of -0.7% year over year.Operating Revenue- Supply Chain Solutions: $1.13 billion versus $1.11 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change.Operating Revenue- Eliminations: $-166 million versus the two-analyst average estimate of $-169.87 million. The reported number represents a year-over-year change of +1.8%.Revenues- Fleet Management Solutions: $1.62 billion versus the two-analyst average estimate of $1.58 billion. The reported number represents a year-over-year change of +10.3%.Revenues- Fleet Management Solutions- SelectCare and other: $187 million compared to the $174.77 million average estimate based on two analysts. The reported number represents a change of +13.3% year over year.Revenues- Dedicated Transportation Solutions: $606 million versus the two-analyst average estimate of $609.87 million. The reported number represents a year-over-year change of +6.3%.Revenues- Eliminations: $-293 million versus $-291.65 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +20.1% change.Revenues- Fleet Management Solutions- Commercial rental: $244 million versus $241.69 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +0.8% change.View all Key Company Metrics for Ryder here>>>
Shares of Ryder have returned +1% over the past month versus the Zacks S&P 500 composite's no change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
In its upcoming report, Ryder (R - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $4.17 per share, reflecting an increase of 16.8% compared to the same period last year. Revenues are forecasted to be $3.4 billion, representing a year-over-year increase of 7.2%.
The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Ryder metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts expect 'Operating Revenue- Fleet Management Solutions' to come in at $1.32 billion. The estimate points to a change of +2.8% from the year-ago quarter.
The average prediction of analysts places 'Operating Revenue- Dedicated Transportation Solutions' at $461.03 million. The estimate indicates a change of +0.7% from the prior-year quarter.
It is projected by analysts that the 'Operating Revenue- Supply Chain Solutions' will reach $1.11 billion. The estimate suggests a change of +7.2% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Supply Chain Solutions (SCS)- Subcontracted transportation and fuel' of $388.56 million. The estimate indicates a change of +12.3% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Fleet Management Solutions' should come in at $1.58 billion. The estimate indicates a year-over-year change of +8.1%.
The consensus estimate for 'Revenues- Fleet Management Solutions- SelectCare and other' stands at $174.77 million. The estimate suggests a change of +5.9% year over year.
The combined assessment of analysts suggests that 'Revenues- Dedicated Transportation Solutions' will likely reach $609.87 million. The estimate indicates a year-over-year change of +7%.
The consensus among analysts is that 'Revenues- Fleet Management Solutions- Commercial rental' will reach $241.69 million. The estimate points to a change of -0.1% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- Fleet Management Solutions- ChoiceLease' reaching $901.21 million. The estimate indicates a change of +3% from the prior-year quarter.
Analysts predict that the 'Revenues- Fleet Management Solutions- Fuel services' will reach $265.99 million. The estimate suggests a change of +45.4% year over year.
Analysts forecast 'Revenues- Supply Chain Solutions' to reach $1.50 billion. The estimate suggests a change of +8.5% year over year.
Based on the collective assessment of analysts, 'Commercial rental - Rental Utilization - Power Units' should arrive at 75.0%. Compared to the current estimate, the company reported 70.0% in the same quarter of the previous year.
View all Key Company Metrics for Ryder here>>>
Over the past month, shares of Ryder have returned -0.5% versus the Zacks S&P 500 composite's +0.7% change. Currently, R carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Akcie společnosti Ryder System za poslední rok vzrostly o 32,1 % a firma v roce 2025 vrátila akcionářům 664 milionů USD, zejména prostřednictvím zpětného odkupu akcií.
Key Takeaways Ryder System shares gained 32.1% in a year, outpacing the equipment and leasing industry's 9.3% growth.R's relocated New Jersey truck centers enhance market reach, customer access and operational efficiency.R returned $664 million to shareholders in 2025, including $519M in buybacks & $145M in dividends. Ryder System (R - Free Report) is benefiting from its proactive expansion initiatives that are boosting the company’s operational efficiency. The company’s commitment to shareholders is encouraging and bodes well for its prospects. Due to these tailwinds, R shares have performed impressively on the bourse. If you have not taken advantage of its share price appreciation yet, it’s time to do so.
Let’s delve deeper.
Factors Favoring R StockNorthward Earnings Estimate Revision: The Zacks Consensus Estimate for earnings per share (EPS) has been revised upward by 14.09% year over year for 2026. For 2027, the consensus mark for EPS has moved 21.5% north over the same time frame. The favorable estimate revisions indicate brokers’ confidence in the stock.
Robust Price Performance: A look at the company’s price trend reveals that its shares have gained 32.1% over the past year, surpassing the Zacks Transportation - Equipment and Leasing industry’s 9.3% growth.
Image Source: Zacks Investment Research
Positive Earnings Surprise History: Ryder System has an encouraging earnings surprise history. The company's earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and missed once in the remaining, delivering an average surprise of 2.53%.
Solid Zacks Rank: R currently carries a Zacks Rank #2 (Buy).
Bullish Industry Rank: The industry to which R belongs currently has a Zacks Industry Rank of 37 (out of 247). Such a favorable rank places it in the top 15% of Zacks Industries. Studies show that 50% of a stock’s price movement is directly related to the performance of the industry group to which it belongs.
A mediocre stock within a strong group is likely to outperform a robust stock in a weak industry. Reckoning the industry’s performance becomes imperative in this context.
Growth Factors: Ryder System is benefiting from its proactive expansion initiatives, strengthening its presence in the Northeast through new and relocated used truck centers in Newark and North Bergen, NJ. These investments enhance customer access to major ports, freight corridors and distribution hubs, positioning the company closer to key logistics markets. The Newark facility is also expected to improve operational efficiency by bringing multiple fleet management solutions under one roof, while the North Bergen location expands Ryder’s reach into a new market south of the George Washington Bridge. These developments could support used vehicle sales and reinforce the company’s integrated transportation service offering.
Ryder’s 2026 E-commerce Consumer Study highlights shifting consumer preferences, with increasing AI adoption, faster delivery expectations and growing demand for seamless omnichannel fulfillment. With 64% of shoppers using AI-assisted tools and 39% expecting delivery within one to two days, retailers face mounting pressure to improve logistics capabilities and fulfillment efficiency. Additionally, the growing popularity of alternative pickup options and flexible returns underscores the importance of integrated supply chain solutions.
These trends create growth opportunities for Ryder’s e-commerce fulfillment, last-mile delivery and omnichannel logistics services as retailers prioritize speed, convenience and customer satisfaction. However, rising delivery expectations and demand for free returns could increase operating costs and pressure profitability. Ryder’s ability to leverage technology-driven logistics solutions and operational efficiencies could strengthen its competitive position and support long-term growth.
Moreover, R’s focus on returning capital to shareholders through dividends and buybacks aligns with its strategy of maintaining a balanced and sustainable growth model. Ryder System returned $456 million in cash to shareholders in 2024 and increased total capital returns to $664 million in 2025, including $519 million in share repurchases and $145 million in cash dividends. The company consistently increased cash dividend payments from $128 million in 2023 to $135 million in 2024 and $145 million in 2025, reflecting strong cash generation and continued emphasis on shareholder returns.
Other Stocks to ConsiderInvestors interested in the Zacks Transportation sector may consider other top-ranked stocks like Wabtec (WAB - Free Report) and Herc Holdings (HRI - Free Report) .
WAB currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
WAB has an expected earnings growth rate of more than 21.4% for 2026. The company has an encouraging earnings surprise history. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 4.18%.
Herc Holdings currently sports a Zacks Rank #1.
HRI has a negative expected earnings growth rate of 7.36% for the current year. However, the company has an encouraging earnings surprise history. Its earnings topped the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 60.64%.
Company Pays Dividend for 201st Consecutive Quarter
MIAMI--(BUSINESS WIRE)--The Board of Directors of Ryder System, Inc. (NYSE: R) declared a regular quarterly cash dividend of $1.01 per share of common stock to be paid on December 18, 2026 to shareholders of record on November 23, 2026.
This is Ryder’s 201st consecutive quarterly cash dividend – marking 50 years of uninterrupted dividend payments.
About Ryder System, Inc.
Ryder System, Inc. (NYSE: R) is a nearly $13 billion leading provider of outsourced logistics and transportation services throughout the United States, Canada, and Mexico. Ryder offers supply chain, dedicated transportation, and fleet management solutions that integrate every step of the supply chain port‑to‑door, including cross-border logistics, fleet and transportation management, warehousing and distribution, and final delivery to customers’ doorsteps. Ryder’s broad portfolio of services encompasses managed transportation, freight brokerage, dedicated contract carriage with professional drivers, full‑service fleet leasing and maintenance, commercial truck rental, automation and robotics, digital technologies, contract manufacturing and packaging, omnichannel retail fulfillment including e-commerce and last-mile delivery, and used vehicle sales. Serving more than 20 industries, Ryder manages approximately 240,000 commercial vehicles, operates nearly 800 maintenance locations, and runs approximately 320 warehouses totaling more than 100 million square feet. Ryder is consistently recognized for technology‑driven innovation and industry‑leading practices in safety, health, security, talent acquisition, and environmental management, and was most recently named to Fortune’s “America’s Most Innovative Companies” list. www.ryder.com
Note Regarding Forward-Looking Statements: Certain statements and information included in this news release are “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current plans and expectations and are subject to risks, uncertainties and assumptions. Accordingly, these forward-looking statements should be evaluated with consideration given to the many risks and uncertainties that could cause actual results and events to differ materially from those in the forward-looking statements including those risks set forth in our periodic filings with the Securities and Exchange Commission. New risks emerge from time to time. It is not possible for management to predict all such risk factors or to assess the impact of such risks on our business. Accordingly, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Ryder otevřel prodejní centrum ojetých nákladních vozů v North Bergenu a přestěhoval středisko z Kearny do většího provozu v Newarku, čímž rozšířil svou síť v severním New Jersey.
Key Takeaways Ryder expands its used truck network with a relocated Newark facility and a new North Bergen sales center.The Newark facility improves port access and operational efficiency, supporting Ryder's port-to-door strategy.R's North Bergen center improves customer access, while both locations offer eligible used vehicle warranties. In a bid to widen its popularity in terms of services and strengthen its position across one of North America’s popular freight markets, Ryder System, Inc. (R - Free Report) announced the launch of two new used truck centers in Newark and North Bergen, NJ. These two investments in northern New Jersey reflect Ryder’s expansion into the used commercial vehicle market.
Ryder has relocated its Kearny used vehicle center to a bigger facility in Newark, NJ, and has opened a new used truck sales center in North Bergen, NJ.
Situated at 474 Wilson Avenue in Newark, the relocated facility strengthens Ryder’s presence in a key freight hub, offering direct access to the Port of Newark, Interstate 95 and Newark Liberty International Airport. By consolidating multiple fleet management solutions under one roof, the facility is expected to enhance operational efficiency and advance Ryder’s integrated port-to-door transportation strategy.
Ryder has expanded its used commercial vehicle sales network with the opening of a new facility at 6214 Tonnelle Avenue in North Bergen, marking its first location south of the George Washington Bridge. Situated along the busy U.S. Route 1-9 corridor near New York City, the facility enhances Ryder’s presence in a major logistics hub, improves accessibility for customers and creates additional opportunities for used vehicle sales.
Eric Upchurch, vice president of vehicle sales at Ryder, stated, “Northern New Jersey is one of the most important transportation markets in North America, making it a natural fit to expand our used vehicle sales network. These locations bring us closer to the customers, carriers, and logistics operations that drive the regional economy and make it easier for customers to access Ryder’s high-quality used vehicle inventory and fleet solutions.”
To ConcludeThe New York-New Jersey region is a critical hub for the U.S. supply chain, facilitating international trade, warehousing, distribution and transportation activities. Given this backdrop, Ryder’s expansion into Newark and North Bergen is expected to strengthen its competitive position in the freight industry.
The new facilities enhance Ryder’s ability to serve customers across the Northeast by improving access to major ports, distribution centers and key transportation networks. Additionally, both locations support the Ryder Vehicle Assurance Program, which offers a complimentary 60-day limited warranty on eligible DOT Verified used vehicles through year-end. These investments should reinforce Ryder’s regional presence, expand customer reach and support its long-term growth prospects.
Ryder’s Zacks Rank and Other Stocks to ConsiderRyder presently carries a Zacks Rank #2 (Buy).
Investors interested in the Zacks Transportation sector may also consider Expeditors International of Washington, Inc. (EXPD - Free Report) and Herc Holdings (HRI - Free Report) .
Expeditors currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
EXPD has an expected earnings growth rate of 28.6% for 2026. The company has an encouraging earnings surprise history. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 17.15%.
Herc Holdings currently sports a Zacks Rank #1.
HRI has a negative expected earnings growth rate of 8.4% for the current year. However, the company has an encouraging earnings surprise history. Its earnings topped the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 60.64%.
Tenon Medical spustila plný komerční prodej nového titanového 3D tištěného šroubu SImmetry+ SI Joint Fusion System pro fúzi sakroiliakálního kloubu. Omezený Alpha launch přinesl zhruba 1,2 milionu USD dodatečných tržeb.
~ SImmetry+ System generated approximately $1.2 million in incremental revenue during limited launch period ~
~ Company plans to support anticipated demand for the SImmetry+ System by expanding its instrument set inventory as needed ~
~ New SImmetry+ 3D printed screw is the first component of a next-generation lateral SI joint fusion system, and the first of several Company product launches expected in the coming quarters ~
LOS GATOS, CA / ACCESS Newswire / September 30, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients with sacro-pelvic disorders, today announced the full commercial launch of its new titanium 3D- printed lateral screw as part of the SImmetry+ SI Joint Fusion System following the successful completion of the implant's Alpha launch. The limited Alpha launch, involving existing SImmetry users and new physicians, generated approximately $1.2 million (1) in incremental revenue for a period beginning in late Q4 2025 through Q3 2026. The Company plans to support anticipated demand for the SImmetry+ System by expanding its instrument set inventory as needed.
Physician feedback from the Alpha launch was positive, with users highlighting the system's new screw design along with the system's ability to decorticate the joint prior to implantation, a step intended to strengthen joint fusion. SImmetry+ is a novel, minimally invasive, lateral and posterior oblique-access SI joint fusion system featuring new 3D-printed titanium implants and proprietary instrumentation. The System is built on established orthopedic principles, including joint decortication, bone graft delivery, and fixation, to achieve fusion of the sacroiliac joint in an efficient manner.
In response to input from Alpha users and newly trained surgeons preparing for their first cases, Tenon has expanded the SImmetry+ portfolio with two additional implant sizes, broadening the range of patient anatomies the system can address.
"We are very pleased with the early performance of the SImmetry+ SI Joint Fusion System and the strong feedback we've received from physician users," said Steven M. Foster, President and CEO of Tenon Medical. "We believe that this milestone supports the strategic rationale behind our acquisition of SImmetry+ in August 2025. Early case volume and revenue generated during the Alpha launch support our view that this platform can be a meaningful growth driver as we move into full commercial launch. Our re-engineered SImmetry+ screw is the first component of a next-generation lateral SI joint fusion system, and the first of several product launches we expect in the coming quarters, each designed to further improve patient outcomes and ease of use."
The choice of surgical approach to the SI joint is typically driven by physician training and experience. Tenon is the only company we know of offering multiple SI joint fusion approaches tailored to user preference: lateral and posterior oblique approaches with the SImmetry+ System, and an inferior-posterior approach with the Catamaran® SI Joint Fusion System. Both platforms are designed to provide immediate fixation, with long-term fusion as the goal. This breadth is intended to allow Tenon to serve a wider range of physicians and expand its reach across the SI joint fusion market.
"The goal of SI joint fusion is to stabilize the joint by reducing the micromotion that causes pain," said Ali Araghi, D.O., orthopedic spine surgeon at The CORE Institute in Phoenix, Arizona. "Achieving a true, long-term fusion of the SI joint can be a key component of favorable patient outcomes. The SImmetry+ System, with its unique 3D-printed implants designed for fixation and stability, allows me to treat the SI joint using principles consistent with traditional orthopedic fusion. I found the instrumentation and implants to be very effective and simple to use in these initial Alpha cases, and I look forward to continued advancements that further improve long-term outcomes and satisfaction for my SI joint patients."
The SImmetry+ and Catamaran® SI Joint Fusion Systems form the cornerstone of Tenon's growing portfolio of advanced technologies. The Company believes that together, they give Tenon a unique position in the market: three minimally invasive surgical approaches, each designed with the goal of achieving true arthrodesis, and supported by clinical evidence from the published prospective MAINSAIL™ and EVoluSIon™ studies. This differentiated portfolio allows physicians to tailor treatment to each patient, and, in the Company's view, positions Tenon to capture a broader share of the SI joint fusion market.
(1) This figure is preliminary and unaudited, is not necessarily indicative of future results.
About Tenon Medical, Inc.
Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon has been focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct.
For more information, please visit www.tenonmed.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release.
The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM is also a trademark of Tenon Medical, Inc.
Safe Harbor
This press release contains "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements include, but are not limited to, statements regarding the anticipated commercial performance, adoption and demand for the SImmetry+ system; the timing of deployment of additional instrument sets; the development and timing of the next-generation lateral SI joint fusion system and future product launches; the SImmetry+ platform as a growth driver; the expected benefits of the Company's acquisition of SiVantage, Inc. and SIMPL Medical, LLC; the Company's market position and ability to expand market share; and anticipated clinical outcomes. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. Readers are cautioned not to place undue reliance on these forward-looking statements. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated from time to time in Tenon's Form 10-Q filings and in Tenon's other public filings on file with the SEC at www.sec.gov, particularly the information contained in the sections entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise, except as required by applicable law.
Investor Contact
Shannon Devine
MZ North America
203-741-8811
[email protected]
Vicapsys Life Sciences dokončila reverzní fúzi se Stateline Distributors of Puerto Rico a podepsala definitivní dohodu o akvizici NitroMist za US$ 2,0 milionu v konvertibilním dlužním úpisu. Firma tím buduje integrovanou farmaceutickou platformu pro distribuci i výrobu.
Stateline is a DSCSA-compliant specialty pharmaceutical wholesale distributor with approximately 400 active healthcare accounts in Puerto Rico and a 50-state title model executed through third-party logistics partner DrugzoneStrategic tribal 8(a) teaming agreement gives the combined company access to set-aside and sole-source federal contracting channels, including Indian Health Service pharmaceutical supplyVICP has signed a definitive agreement to acquire NitroMist® (nitroglycerin) lingual aerosol, NDA 021780, for a US$2.0million convertible note and is preparing stability, medium-fill and pre-production batches with its contract manufacturing partner for the product's relaunchCompany in discussions to acquire an approximately 120,000-square-foot former big-pharma API manufacturing facility in Puerto Rico, including 50,000 square feet of cleanroom manufacturing space and 70,000 square feet of distribution space MIAMI, FL AND SAN JUAN, PUERTO RICO / ACCESS Newswire / September 22, 2026 / Vicapsys Life Sciences, Inc. (OTC PINK:VICP) ("VICP" or the "Company") today announced that it has completed its reverse merger with Stateline Distributors of Puerto Rico, Inc. ("Stateline"), effective September 3, 2026, and has entered into a definitive asset purchase agreement to acquire the FDA-approved NitroMist® (nitroglycerin) lingual aerosol product. Stateline is now a wholly owned subsidiary of VICP. The combined company is organized as a pharmaceutical platform that pairs licensed wholesale distribution and federal contracting access with owned branded products and, following the planned facility acquisition described below, in-house manufacturing.
Under the terms of the merger agreement, executed on August 12, 2026, Stateline's shareholders received shares of newly designated Series C Convertible Preferred Stock of VICP. Additional information regarding the merger and the NitroMist asset purchase agreement will be made available through the OTC Markets Disclosure & News Service at www.otcmarkets.com.
Stateline: Licensed Distribution Base with 50-State Reach
Stateline (Instagram@STLNIPO) is a specialty pharmaceutical wholesale distributor headquartered in San Juan, Puerto Rico, operating in compliance with the FDA-administered Drug Supply Chain Security Act (DSCSA). Stateline holds Puerto Rico wholesale drug distributor and biologics licenses and serves approximately 400 active healthcare accounts across the island.
Beyond Puerto Rico, Stateline operates a 50-state title model: Stateline takes title to product and fulfills through Drugzone, a 50-state-licensed, NABP-accredited third-party logistics provider. This structure gives Stateline nationwide distribution reach without the capital and time required to build licensed warehouses in each state, and allows the Company to place product with customers anywhere in the United States under a single DSCSA-compliant chain of custody.
Tribal 8(a) Teaming Agreement: Access to Set-Aside and Sole-Source Federal Channels
Stateline has a strategic teaming agreement with a tribally owned, SBA-certified 8(a) partner. Tribally owned 8(a) firms are eligible for sole-source federal contract awards above the competitive thresholds that apply to other 8(a) participants, and for set-aside procurements, including Buy Indian Act set-asides used by the Indian Health Service (IHS).
The teaming agreement vertically integrates Stateline's licensed distribution channel and procurement bandwidth with the partner's federal contracting eligibility. Through the partner, the combined company can pursue set-aside solicitations and sole-source awards, and can monetize IHS pharmaceutical supply contracts from a wholesale drug distribution perspective, supplying IHS federal facilities and tribally operated health programs with the products those contracts require.
Rural, tribal, IHS, Veterans Affairs, Department of Defense and Puerto Rico markets are structurally underserved by the three national wholesalers. The Company's strategy is to be the specialized distributor for these channels and, with in-house manufacturing, the specialized manufacturer as well.
NitroMist® Acquisition and Relaunch
VICP has entered into a definitive asset purchase agreement with KCK Sunshine, LLC to acquire NitroMist® (nitroglycerin) lingual aerosol, NDA 021780, a sublingual nitroglycerin spray indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. The assets to be acquired include the NDA, the NitroMist® trademark, global licensing, marketing and commercialization rights, and the product's formulation, manufacturing and stability know-how. NitroMist was previously marketed in the United States, was voluntarily discontinued by a prior owner effective December 31, 2022, for reasons unrelated to safety or effectiveness, and is not currently available to patients. The NDA remains approved and in effect.
Consideration for the acquisition is a US$2.0million convertible promissory note to be issued by VICP at closing. The note bears simple interest at 15% per annum, matures five years from issuance, and is convertible at the holder's option into VICP common stock at US$1.00 per share during the 36 months following issuance, with accrued interest converting together with principal. VICP may require conversion if the volume-weighted average price of its common stock equals or exceeds US$2.50 per share for 20 consecutive trading days during that period.
Closing is subject to customary conditions, including delivery of chain-of-title documentation for the NDA, FDA's acknowledgment of the transfer of the NDA to the seller, which has been submitted to FDA and is pending, and the NDA being current on annual reports and FDA user fees. At closing, the seller and VICP will submit the transfer-of-ownership and acceptance letters to FDA under FDA's change-of-ownership procedures (21 C.F.R. § 314.72) to transfer the NDA to VICP.
In preparation for the relaunch, VICP is working with its key contract manufacturing (CMO) partner to produce stability batches, medium-fill batches and pre-production batches of NitroMist. Returning the product to market will also require re-establishment of the manufacturing and supply chain, registration and process-validation batches, current stability data, an FDA supplement reflecting manufacturing changes since approval, and re-listing of the product's National Drug Code.
NitroMist is intended to be the Company's first owned branded product and to be distributed through Stateline's commercial channels and through the federal and tribal channels described above.
Manufacturing: Discussions to Acquire ~120,000 sq ft Puerto Rico Facility
VICP is currently in discussions to acquire an approximately 120,000-square-foot pharmaceutical manufacturing facility in Puerto Rico, formerly operated as an active pharmaceutical ingredient (API) manufacturing site by a major pharmaceutical company. The facility includes approximately 50,000 square feet of cleanroom manufacturing space and approximately 70,000 square feet of warehouse and distribution space.
Following restoration and requalification of the cleanrooms and FDA inspection, the facility is expected to give VICP the ability to manufacture NitroMist in-house, removing the Company's dependence on third-party manufacturing for its lead product. Beyond NitroMist, the cleanroom capacity provides a scalable manufacturing base intended to position the Company as a primary manufacturing-and-distribution source when IHS, the U.S. Department of Health and Human Services (HHS) and other federal agencies issue requests for proposals for specific drug products.
The combination of licensed distribution in Puerto Rico and across all 50 states, federal set-aside contracting access, an owned NDA and domestic manufacturing capacity is designed to allow VICP to respond to federal solicitations as a single integrated supplier: manufacturing the product, holding title to it and delivering it to the point of care.
Management Commentary
"Completing the Stateline merger gives VICP a licensed, revenue-generating operating base and a set of channels the national wholesalers have never prioritized," said Armando Rubio, Chairman and Chief Executive Officer of VICP. "With Stateline's 50-state title model, our tribal 8(a) teaming agreement, the definitive agreement to acquire NitroMist as our first owned product, and the Puerto Rico facility we are working to acquire, we are building a company that can manufacture, hold title to and deliver drugs for federal, tribal and underserved markets under one roof. Our immediate priorities are closing the NitroMist acquisition and getting the product back on the market, and closing on the facility. In parallel, Stateline will continue to pursue distribution opportunities in underserved markets, with full DSCSA compliance as the foundation of every product we ship."
Leadership
In connection with the closing, Armando Rubio serves as Chairman and Chief Executive Officer of VICP; Jean Dominguez as President; Alberto Dominguez as Chief Financial Officer; David Wayne Dunn as Executive Vice President of Sales; and Humberto Borque as Director of Economic Development for NitroMist. At Stateline, Prakash Pathare serves as Executive Sales Director and Angel L. Melendez as Pharmacist-in-Charge and licensed pharmacist of record. Federico Pier, VICP's former Chief Executive Officer, resigned from his positions with the Company in connection with the closing.
VICAPSYN™: Legacy Biotechnology Program Retained
In connection with the merger, VICP retains its legacy biotechnology program, VICAPSYN™, together with the Company's exclusive license from Massachusetts General Hospital for the underlying CXCL12 technology, as a continuing asset of the Company. The program targets the foreign body response, a biological mechanism responsible for implant rejection and fibrosis.
Retaining the program preserves shareholder optionality in the biotechnology asset and reflects the Company's commitment to maximizing value across both its pharmaceutical distribution platform and its legacy life sciences portfolio. The Company will describe any material developments in the program, including any change in the entity through which it is held, in its public disclosures.
Advisory Board
The Company is also onboarding the following members to its board of advisors:
Moe Vela, two-time White House senior advisorDr. Makarand(Mak) Jadawakar, former Pfizer scientist with nearly three decades at the companyDr. Ismael Torres, former head of oncology for Puerto RicoMariano Dall'Orso, former Global Senior Vice President at Western UnionLuis Rey and Gustavo Koniszczer, Managing Partners of FutureBrand Latin AmericaRobert Ojeida, senior executive at K&B Associates, a group purchasing organization, and pharmaceutical industry executiveAbout Vicapsys Life Sciences, Inc.
Vicapsys Life Sciences, Inc. (OTC: VICP) is a publicly traded pharmaceutical platform company headquartered in Miami, Florida, with operations in San Juan, Puerto Rico. Through its wholly owned subsidiary, Stateline Distributors of Puerto Rico, Inc., VICP operates a DSCSA-compliant specialty pharmaceutical wholesale distribution business with a 50-state title model, and holds a strategic teaming agreement with a tribally owned 8(a) partner for federal set-aside and sole-source contracting. VICP's strategy is to build an integrated manufacturing and distribution platform serving rural, tribal, Indian Health Service, Veterans Affairs, Department of Defense and Puerto Rico markets, anchored by owned branded products, beginning with NitroMist®, which the Company has agreed to acquire. VICP also retains its legacy biotechnology program, VICAPSYN™, under the Company's exclusive license from Massachusetts General Hospital.
About Stateline Distributors of PuertoRico, Inc.
Stateline Distributors of Puerto Rico, Inc. is a specialty pharmaceutical wholesale distributor based in San Juan, Puerto Rico. Stateline holds Puerto Rico wholesale drug distributor and biologics licenses, operates in compliance with the DSCSA, serves approximately 400 active healthcare accounts, and extends its reach to all 50 states through a title model executed with third-party logistics partner Drugzone.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, without limitation, statements regarding the Company's strategy and expected benefits of the merger; the closing of the NitroMist acquisition and the satisfaction of its closing conditions, including FDA's acknowledgment of the transfers of the NDA; the timing and success of the NitroMist relaunch; the proposed acquisition of the Puerto Rico manufacturing facility and the timing, cost and outcome of its restoration, requalification and FDA inspection; the Company's ability to obtain federal, tribal or Indian Health Service contracts through its teaming agreement; expected manufacturing and distribution capacity; the value of, and any future development of or strategic transaction involving, the VICAPSYN program and the Company's license from Massachusetts General Hospital; and the Company's ability to raise the capital required to execute its plans. Words such as "expects," "intends," "plans," "positions," "designed to," "preserves," "will," "may" and similar expressions identify forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including: the NitroMist acquisition may not close on the terms described or at all; the facility acquisition may not be completed on the terms described or at all; FDA may not acknowledge the NDA transfers or approve required supplements on the anticipated timeline; manufacturing, stability and regulatory activities for NitroMist may be delayed or unsuccessful; federal and tribal contract awards are not assured; the VICAPSYN program may not advance or realize value, and the Company's license may be subject to termination or other adverse action; the Company may be unable to obtain financing on acceptable terms; and other risks and uncertainties affecting the Company's business. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.
Contact
Vicapsys Life Sciences, Inc.
Armando Rubio
Chairman and Chief Executive Officer
[email protected]
(305) 565-8002
Bank of America Corp DE bought a new stake in shares of Ryder System, Inc. (NYSE:R – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 787,388 shares of the transportation company’s stock, valued at approximately $207,689,000. Bank of America Corp DE owned 2.05% of Ryder System as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Ryder System during the 2nd quarter worth about $1,060,749,000. Norges Bank purchased a new stake in Ryder System in the 4th quarter worth approximately $111,168,000. Bank of New York Mellon Corp acquired a new stake in shares of Ryder System during the 2nd quarter valued at $136,320,000. First Trust Advisors LP boosted its stake in shares of Ryder System by 81.5% during the 1st quarter. First Trust Advisors LP now owns 1,010,320 shares of the transportation company’s stock valued at $206,822,000 after buying an additional 453,697 shares during the period. Finally, NewEdge Wealth LLC purchased a new position in shares of Ryder System during the 2nd quarter valued at $74,531,000. Hedge funds and other institutional investors own 87.47% of the company’s stock.
Wall Street Analysts Forecast Growth Several brokerages recently issued reports on R. Barclays increased their price objective on Ryder System from $290.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Susquehanna boosted their target price on Ryder System from $290.00 to $310.00 and gave the company a “positive” rating in a research note on Friday, July 24th. Zacks Research lowered Ryder System from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 22nd. Citigroup raised their price target on Ryder System from $280.00 to $283.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Ryder System in a report on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $294.14.
View Our Latest Stock Analysis on R Ryder System Stock Down 1.3% NYSE R opened at $238.08 on Thursday. Ryder System, Inc. has a twelve month low of $157.67 and a twelve month high of $284.25. The stock has a market cap of $9.13 billion, a PE ratio of 19.37 and a beta of 1.01. The firm has a 50-day simple moving average of $257.07 and a 200 day simple moving average of $242.52. The company has a debt-to-equity ratio of 1.91, a quick ratio of 0.65 and a current ratio of 0.65.
Ryder System (NYSE:R – Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The transportation company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.69 by $0.04. Ryder System had a net margin of 3.88% and a return on equity of 18.28%. The firm had revenue of $2.69 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same quarter in the previous year, the firm posted $3.32 EPS. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. Ryder System has set its FY 2026 guidance at 14.400-14.800 EPS and its Q3 2026 guidance at 4.000-4.200 EPS. On average, research analysts forecast that Ryder System, Inc. will post 14.74 EPS for the current year.
Ryder System Increases Dividend The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 18th. Shareholders of record on Monday, August 24th will be paid a dividend of $1.01 per share. This is an increase from Ryder System’s previous quarterly dividend of $0.91. This represents a $4.04 annualized dividend and a yield of 1.7%. The ex-dividend date is Monday, August 24th. Ryder System’s dividend payout ratio is currently 32.87%.
Ryder System Profile (Free Report)
Ryder System, Inc is a transportation and logistics company that provides fleet management, supply chain and dedicated transportation services. The company serves commercial customers across industries, helping them manage the movement, storage and delivery of goods through integrated transportation and logistics solutions.
Ryder’s fleet management offerings include commercial truck leasing, rental, maintenance and related support services. It also sells used vehicles and provides technology designed to help customers monitor fleets, improve utilization and manage transportation operations.
Read More Five stocks we like better than Ryder System 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector Jackson’s Record Quarter Powers the Bull Case Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact Want to see what other hedge funds are holding R? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ryder System, Inc. (NYSE:R – Free Report).
Receive News & Ratings for Ryder System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryder System and related companies with MarketBeat.com's FREE daily email newsletter.
Squarepoint Ops LLC ve 2. čtvrtletí snížila podíl v Ryder System o 66,1 % a prodala 20 177 akcií. Po prodeji držela 10 331 akcií. Ryder zároveň oznámila vyšší kvartální dividendu na 1,01 USD na akcii.
Squarepoint Ops LLC decreased its stake in shares of Ryder System, Inc. (NYSE:R – Free Report) by 66.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,331 shares of the transportation company’s stock after selling 20,177 shares during the quarter. Squarepoint Ops LLC’s holdings in Ryder System were worth $2,725,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the stock. Royal Bank of Canada grew its position in Ryder System by 52.8% during the 1st quarter. Royal Bank of Canada now owns 15,765 shares of the transportation company’s stock valued at $2,267,000 after purchasing an additional 5,448 shares during the last quarter. Focus Partners Wealth increased its position in shares of Ryder System by 7.9% during the first quarter. Focus Partners Wealth now owns 1,851 shares of the transportation company’s stock valued at $266,000 after acquiring an additional 135 shares in the last quarter. Geneos Wealth Management Inc. increased its position in shares of Ryder System by 61.2% during the first quarter. Geneos Wealth Management Inc. now owns 287 shares of the transportation company’s stock valued at $41,000 after acquiring an additional 109 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Ryder System by 10.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,191 shares of the transportation company’s stock worth $189,000 after acquiring an additional 110 shares during the last quarter. Finally, M&T Bank Corp raised its holdings in Ryder System by 10.9% in the 2nd quarter. M&T Bank Corp now owns 2,153 shares of the transportation company’s stock worth $343,000 after acquiring an additional 212 shares during the last quarter. 87.47% of the stock is owned by institutional investors.
Ryder System Trading Up 0.2% NYSE:R opened at $243.67 on Monday. The company has a market cap of $9.34 billion, a PE ratio of 19.83 and a beta of 1.01. The company has a current ratio of 0.65, a quick ratio of 0.65 and a debt-to-equity ratio of 1.91. The company has a 50 day simple moving average of $258.51 and a two-hundred day simple moving average of $242.15. Ryder System, Inc. has a 12 month low of $157.67 and a 12 month high of $284.25.
Ryder System (NYSE:R – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The transportation company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.69 by $0.04. The firm had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Ryder System had a return on equity of 18.28% and a net margin of 3.88%.The company’s revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.32 EPS. Ryder System has set its FY 2026 guidance at 14.400-14.800 EPS and its Q3 2026 guidance at 4.000-4.200 EPS. Research analysts forecast that Ryder System, Inc. will post 14.74 earnings per share for the current year. Ryder System Increases Dividend The company also recently declared a quarterly dividend, which will be paid on Friday, September 18th. Shareholders of record on Monday, August 24th will be paid a dividend of $1.01 per share. The ex-dividend date is Monday, August 24th. This represents a $4.04 dividend on an annualized basis and a dividend yield of 1.7%. This is an increase from Ryder System’s previous quarterly dividend of $0.91. Ryder System’s dividend payout ratio is presently 32.87%.
Analyst Upgrades and Downgrades R has been the topic of several recent analyst reports. Wells Fargo & Company increased their target price on Ryder System from $290.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Citigroup boosted their price target on Ryder System from $280.00 to $283.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Wall Street Zen downgraded Ryder System from a “strong-buy” rating to a “buy” rating in a report on Saturday. Stephens raised Ryder System to a “strong-buy” rating in a research report on Wednesday, July 8th. Finally, Susquehanna lifted their price objective on Ryder System from $290.00 to $310.00 and gave the stock a “positive” rating in a report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $294.14.
View Our Latest Analysis on Ryder System
Ryder System Profile (Free Report)
Ryder System, Inc is a transportation and logistics company that provides fleet management, supply chain and dedicated transportation services. The company serves commercial customers across industries, helping them manage the movement, storage and delivery of goods through integrated transportation and logistics solutions.
Ryder’s fleet management offerings include commercial truck leasing, rental, maintenance and related support services. It also sells used vehicles and provides technology designed to help customers monitor fleets, improve utilization and manage transportation operations.
Featured Stories Five stocks we like better than Ryder System Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound 3 Small-Cap Biotechs With Binary Catalysts on the Calendar Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Ryder System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryder System and related companies with MarketBeat.com's FREE daily email newsletter.
Callan Family Office LLC ve 2. čtvrtletí získala novou pozici v Ryder System za zhruba 812 000 USD. Společnost zároveň oznámila vyšší čtvrtletní dividendu na 1,01 USD na akcii.
Callan Family Office LLC bought a new position in shares of Ryder System, Inc. (NYSE:R – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,079 shares of the transportation company’s stock, valued at approximately $812,000.
A number of other institutional investors have also recently added to or reduced their stakes in R. Keating Financial Advisory Services Inc. bought a new position in Ryder System during the 2nd quarter valued at $26,000. Allworth Financial LP bought a new stake in shares of Ryder System in the 2nd quarter worth $11,498,000. Advisors Preferred LLC bought a new stake in shares of Ryder System in the 2nd quarter worth $1,974,000. Vise Technologies Inc. acquired a new stake in shares of Ryder System in the second quarter valued at $1,502,000. Finally, Denali Advisors LLC acquired a new stake in shares of Ryder System in the second quarter valued at $609,000. 87.47% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In A number of research analysts recently issued reports on R shares. Wells Fargo & Company lifted their target price on Ryder System from $290.00 to $300.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Zacks Research cut shares of Ryder System from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 22nd. Wall Street Zen raised shares of Ryder System from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Morgan Stanley raised their price objective on shares of Ryder System from $263.00 to $280.00 and gave the company an “overweight” rating in a research report on Monday, July 6th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Ryder System from $259.00 to $296.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Ryder System currently has a consensus rating of “Moderate Buy” and an average target price of $294.14.
View Our Latest Analysis on R Ryder System Stock Performance R opened at $244.93 on Tuesday. The firm has a market cap of $9.39 billion, a PE ratio of 19.93 and a beta of 1.02. The company has a quick ratio of 0.65, a current ratio of 0.65 and a debt-to-equity ratio of 1.91. The business has a fifty day simple moving average of $263.78 and a 200-day simple moving average of $239.24. Ryder System, Inc. has a fifty-two week low of $157.67 and a fifty-two week high of $284.25.
Ryder System (NYSE:R – Get Free Report) last issued its earnings results on Thursday, July 23rd. The transportation company reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.69 by $0.04. Ryder System had a return on equity of 18.28% and a net margin of 3.88%.The business had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the previous year, the firm posted $3.32 EPS. The company’s quarterly revenue was up 5.0% on a year-over-year basis. Ryder System has set its FY 2026 guidance at 14.400-14.800 EPS and its Q3 2026 guidance at 4.000-4.200 EPS. As a group, equities analysts predict that Ryder System, Inc. will post 14.74 EPS for the current fiscal year.
Ryder System Increases Dividend The business also recently declared a quarterly dividend, which will be paid on Friday, September 18th. Investors of record on Monday, August 24th will be paid a $1.01 dividend. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 dividend on an annualized basis and a yield of 1.6%. This is an increase from Ryder System’s previous quarterly dividend of $0.91. Ryder System’s dividend payout ratio (DPR) is 29.62%.
Insider Transactions at Ryder System In other Ryder System news, SVP Sanford J. Hodes sold 595 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $251.95, for a total transaction of $149,910.25. Following the completion of the sale, the senior vice president directly owned 22,948 shares of the company’s stock, valued at approximately $5,781,748.60. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.90% of the company’s stock.
Ryder System Profile (Free Report)
Ryder System, Inc is a leading provider of transportation and supply chain management solutions, serving commercial customers across a range of industries. The company’s Fleet Management Solutions segment offers full-service leasing and rental of medium- and heavy-duty trucks, tractors and trailers, along with maintenance and repair services at its network of service locations. Its Supply Chain Solutions segment provides integrated, technology-driven offerings that span managed transportation, dedicated contract carriage, warehousing and distribution, and e-commerce fulfillment.
Founded in 1933 and headquartered in Miami, Florida, Ryder has grown from a regional truck leasing operation into a diversified, global logistics provider.
Featured Articles Five stocks we like better than Ryder System Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Snowflake Could Be Headed for New Highs Despite Insider Selling MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Ryder System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryder System and related companies with MarketBeat.com's FREE daily email newsletter.
BlackRock Inc. purchased a new stake in Ryder System, Inc. (NYSE:R – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 4,021,493 shares of the transportation company’s stock, valued at approximately $1,060,749,000. BlackRock Inc. owned approximately 10.49% of Ryder System at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of R. Calamos Wealth Management LLC bought a new position in Ryder System during the 4th quarter valued at $1,408,000. Arrowstreet Capital Limited Partnership increased its position in shares of Ryder System by 9.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 194,632 shares of the transportation company’s stock worth $39,843,000 after purchasing an additional 16,070 shares during the last quarter. Braun Stacey Associates Inc. acquired a new stake in shares of Ryder System in the 1st quarter valued at about $12,189,000. NewEdge Wealth LLC lifted its position in shares of Ryder System by 2.9% during the fourth quarter. NewEdge Wealth LLC now owns 250,334 shares of the transportation company’s stock worth $47,911,000 after purchasing an additional 6,952 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in shares of Ryder System by 23.6% during the first quarter. California State Teachers Retirement System now owns 48,030 shares of the transportation company’s stock worth $9,832,000 after purchasing an additional 9,179 shares during the last quarter. Institutional investors and hedge funds own 87.47% of the company’s stock.
Ryder System Trading Up 0.6% NYSE:R opened at $249.44 on Friday. The stock has a market cap of $9.57 billion, a PE ratio of 20.30 and a beta of 1.02. The company has a debt-to-equity ratio of 1.91, a current ratio of 0.65 and a quick ratio of 0.65. The stock’s 50-day moving average is $264.42 and its two-hundred day moving average is $238.70. Ryder System, Inc. has a fifty-two week low of $157.67 and a fifty-two week high of $284.25.
Ryder System (NYSE:R – Get Free Report) last issued its earnings results on Thursday, July 23rd. The transportation company reported $3.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.69 by $0.04. Ryder System had a net margin of 3.88% and a return on equity of 18.28%. The company had revenue of $2.69 billion during the quarter, compared to analyst estimates of $3.29 billion. During the same quarter last year, the business posted $3.32 EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. Ryder System has set its FY 2026 guidance at 14.400-14.800 EPS and its Q3 2026 guidance at 4.000-4.200 EPS. As a group, equities research analysts forecast that Ryder System, Inc. will post 14.74 earnings per share for the current fiscal year. Ryder System Increases Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 18th. Investors of record on Monday, August 24th will be given a dividend of $1.01 per share. The ex-dividend date of this dividend is Monday, August 24th. This is a boost from Ryder System’s previous quarterly dividend of $0.91. This represents a $4.04 annualized dividend and a yield of 1.6%. Ryder System’s payout ratio is 29.62%.
Insider Transactions at Ryder System In other Ryder System news, SVP Sanford J. Hodes sold 595 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $251.95, for a total value of $149,910.25. Following the completion of the sale, the senior vice president directly owned 22,948 shares of the company’s stock, valued at $5,781,748.60. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.90% of the stock is owned by company insiders.
Analysts Set New Price Targets Several research firms have weighed in on R. Robert W. Baird boosted their target price on shares of Ryder System from $253.00 to $290.00 and gave the company an “outperform” rating in a research note on Wednesday, June 17th. Weiss Ratings restated a “buy (b)” rating on shares of Ryder System in a research report on Wednesday, May 27th. Citigroup lifted their price target on shares of Ryder System from $280.00 to $283.00 and gave the company a “neutral” rating in a report on Friday, July 24th. JPMorgan Chase & Co. boosted their price objective on shares of Ryder System from $259.00 to $296.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Finally, Zacks Research cut shares of Ryder System from a “strong-buy” rating to a “hold” rating in a report on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Ryder System currently has a consensus rating of “Moderate Buy” and an average price target of $294.14.
Check Out Our Latest Report on Ryder System
Ryder System Company Profile (Free Report)
Ryder System, Inc is a leading provider of transportation and supply chain management solutions, serving commercial customers across a range of industries. The company’s Fleet Management Solutions segment offers full-service leasing and rental of medium- and heavy-duty trucks, tractors and trailers, along with maintenance and repair services at its network of service locations. Its Supply Chain Solutions segment provides integrated, technology-driven offerings that span managed transportation, dedicated contract carriage, warehousing and distribution, and e-commerce fulfillment.
Founded in 1933 and headquartered in Miami, Florida, Ryder has grown from a regional truck leasing operation into a diversified, global logistics provider.
Recommended Stories Five stocks we like better than Ryder System Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Ryder System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryder System and related companies with MarketBeat.com's FREE daily email newsletter.
Zomedica se v Kanadě spojila s Boehringer Ingelheim Animal Health Canada Inc. na rozšíření testování PPID u koní pomocí platformy TRUFORMA. Program má veterinářům nabídnout rychlé endokrinní testy přímo v ordinaci a začíná s podzimní testovací sezónou pomocí testů eACTH a inzulinových testů.
Collaboration with one of the world's largest animal health companies expected to accelerate TRUFORMA adoption, expand installed base, and drive recurring diagnostic revenue in Canada
ANN ARBOR, MI / ACCESS Newswire / August 13, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic solutions for equine and companion animals, today announced a collaboration with Boehringer Ingelheim Animal Health Canada Inc., a leader in the animal health industry, to enhance the early detection, treatment, and monitoring of pituitary pars intermedia dysfunction (PPID) in horses across Canada.
Through this initiative, the TRUFORMA system will support Boehringer Ingelheim's PPID awareness and testing efforts in Canada beginning with this fall testing season, enabling veterinarians to perform rapid endocrine testing at the point of care using Zomedica's equine endogenous ACTH (eACTH) and equine insulin assays.
By bringing this testing directly into equine veterinary practices, the program will support prompt diagnosis and treatment. The use of Zomedica's TRUFORMA diagnostic platform within Boehringer Ingelheim's PPID awareness and testing efforts brings advantages for Canadian veterinarians and horse owners alike.
Under the agreement, Zomedica will support the placement of TRUFORMA analyzers in participating equine veterinary practices across Canada, while Boehringer Ingelheim will provide eligible customers with complimentary diagnostic testing performed using Zomedica's TRUFORMA platform.
Participation in the program includes no-cost placement of TRUFORMA analyzers in participating equine veterinary practices, along with diagnostic cartridge kits provided at no cost to eligible Boehringer Ingelheim customers. This approach is expected to expand the installed base of Zomedica's platform in Canada and introduce participating veterinarians to additional equine assays available from Zomedica, including Cortisol and Progesterone.
PPID, previously known as equine Cushing's disease, is the most common endocrine disorder in aging horses, affecting approximately 20-25% of horses over the age of 15. This prevalence has been documented in multiple epidemiological studies, including research published in the Journal of Veterinary Internal Medicine, which reported that roughly one-fifth of horses over 15 years of age show evidence of PPID based on endocrine testing (McFarlane et al., Journal of Veterinary Internal Medicine, 2018).
The program will utilize Zomedica's TRUFORMA® equine endogenous ACTH (eACTH) assay, which recent comparative evaluation data has demonstrated to have the closest agreement to reference laboratory results when compared with other commercially available assays, supporting its reliability for diagnosing PPID and monitoring treatment response.
"Expanding our collaboration with Boehringer Ingelheim-one of the largest and most respected companies in global animal health-into Canada, represents another important milestone for Zomedica," said Kevin Klass, Senior Vice President, Sales at Zomedica. "Their leadership in equine medicine, combined with our TRUFORMA diagnostic technology, creates a powerful synergy and marks another critical step in our strategy. Canada's vast geography and dispersed equine veterinary practices make access to specialized testing more challenging. Bringing this capability into the clinic will reduce the impact of distance and geographic isolation, facilitating timely testing."
"Veterinarians play a critical role in recognizing and managing PPID, and we've seen the meaningful difference that early diagnosis, treatment, and whole-horse management can make," commented Randy Trumpler, Business Unit Director - Equine at Boehringer Ingelheim Animal Health Canada Inc. "By collaborating with Zomedica, we're expanding access to innovative diagnostic solutions for Canadian veterinarians and empowering them to make faster, more confident decisions-ultimately supporting better outcomes for the horses in their care and their owners."
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi Loop® line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VETGuardian PLUSTM Zero Touch® monitoring system and VETIGEL® hemostatic gel, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 17% in 2025 to $32 million, 36% through the six months ended June 30, 2026 to $18 million, and maintains a strong balance sheet with approximately $44 million in liquidity as of June 30, 2026. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 500 people across Canada. Learn more at www.boehringer-ingelheim.com.
About Boehringer Ingelheim (Canada)
Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals and society. Learn more at www.boehringer-ingelheim.com/ca/animal-health.
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, including adoption of our AI technology for microscopy, and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
California State Teachers Retirement System v 1. čtvrtletí zvýšil svůj podíl ve společnosti Ryder System o 23,6 % na 48 030 akcií. Firma zároveň oznámila čtvrtletní dividendu ve výši 1,01 USD na akcii.
California State Teachers Retirement System boosted its position in Ryder System, Inc. (NYSE:R – Free Report) by 23.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 48,030 shares of the transportation company’s stock after purchasing an additional 9,179 shares during the period. California State Teachers Retirement System owned about 0.12% of Ryder System worth $9,832,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Royal Bank of Canada raised its position in Ryder System by 52.8% in the first quarter. Royal Bank of Canada now owns 15,765 shares of the transportation company’s stock worth $2,267,000 after acquiring an additional 5,448 shares during the period. Focus Partners Wealth grew its position in shares of Ryder System by 7.9% during the 1st quarter. Focus Partners Wealth now owns 1,851 shares of the transportation company’s stock valued at $266,000 after acquiring an additional 135 shares during the period. Geneos Wealth Management Inc. increased its stake in shares of Ryder System by 61.2% in the 1st quarter. Geneos Wealth Management Inc. now owns 287 shares of the transportation company’s stock worth $41,000 after purchasing an additional 109 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in shares of Ryder System by 10.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,191 shares of the transportation company’s stock worth $189,000 after purchasing an additional 110 shares in the last quarter. Finally, M&T Bank Corp raised its holdings in Ryder System by 10.9% in the 2nd quarter. M&T Bank Corp now owns 2,153 shares of the transportation company’s stock worth $343,000 after purchasing an additional 212 shares during the period. 87.47% of the stock is currently owned by institutional investors.
Insider Activity at Ryder System In other Ryder System news, SVP Sanford J. Hodes sold 595 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $251.95, for a total transaction of $149,910.25. Following the sale, the senior vice president directly owned 22,948 shares of the company’s stock, valued at $5,781,748.60. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.90% of the company’s stock.
Analyst Ratings Changes R has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price objective on Ryder System from $259.00 to $296.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Citizens Jmp assumed coverage on shares of Ryder System in a report on Wednesday, July 15th. They issued a “market perform” rating for the company. Wall Street Zen upgraded shares of Ryder System from a “hold” rating to a “buy” rating in a research note on Saturday, April 25th. Susquehanna lifted their price target on shares of Ryder System from $290.00 to $310.00 and gave the company a “positive” rating in a report on Friday, July 24th. Finally, Robert W. Baird upped their price target on shares of Ryder System from $253.00 to $290.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $294.14.
Check Out Our Latest Stock Report on Ryder System
Ryder System Stock Performance NYSE R opened at $262.77 on Tuesday. The stock has a market capitalization of $10.08 billion, a PE ratio of 21.38 and a beta of 1.02. The business has a 50 day simple moving average of $265.20 and a two-hundred day simple moving average of $232.27. The company has a debt-to-equity ratio of 1.91, a current ratio of 0.65 and a quick ratio of 0.65. Ryder System, Inc. has a 1-year low of $157.67 and a 1-year high of $284.25.
Ryder System (NYSE:R – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The transportation company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.69 by $0.04. The business had revenue of $2.69 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Ryder System had a return on equity of 18.28% and a net margin of 3.88%.The company’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm earned $3.32 EPS. Ryder System has set its FY 2026 guidance at 14.400-14.800 EPS and its Q3 2026 guidance at 4.000-4.200 EPS. On average, research analysts predict that Ryder System, Inc. will post 14.74 EPS for the current fiscal year.
Ryder System Increases Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, September 18th. Stockholders of record on Monday, August 24th will be given a dividend of $1.01 per share. The ex-dividend date is Monday, August 24th. This represents a $4.04 annualized dividend and a dividend yield of 1.5%. This is a positive change from Ryder System’s previous quarterly dividend of $0.91. Ryder System’s dividend payout ratio is currently 29.62%.
Ryder System Profile (Free Report)
Ryder System, Inc is a leading provider of transportation and supply chain management solutions, serving commercial customers across a range of industries. The company’s Fleet Management Solutions segment offers full-service leasing and rental of medium- and heavy-duty trucks, tractors and trailers, along with maintenance and repair services at its network of service locations. Its Supply Chain Solutions segment provides integrated, technology-driven offerings that span managed transportation, dedicated contract carriage, warehousing and distribution, and e-commerce fulfillment.
Founded in 1933 and headquartered in Miami, Florida, Ryder has grown from a regional truck leasing operation into a diversified, global logistics provider.
Featured Articles Five stocks we like better than Ryder System SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Why Rare Earth Processing Could Be the Real 2027 Opportunity The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Ryder System Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ryder System and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECalifornia State Teachers Retirement System Acquires 38,300 Shares of Knight-Swift Transportation Holdings Inc. $KNX
NEXT HEADLINE »Geron (GERN) Expected to Announce Quarterly Earnings on Wednesday
DataMeds AI spustila přes Corexa Pharmacy přímý prodej Tollovid® a Galactovid™ pro akutní virové infekce a Long COVID. Firma zároveň oznámila distribuční dohodu s Tollo Health.
Launch targets acute viral infection and Long COVID markets through www.CorexaRx.com/Store
TAMPA, FL / ACCESS Newswire / July 31, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI" or the "Company"), a Health IT company leveraging its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the compliant monetization of health data by market participants, today announced that its wholly-owned online pharmacy, Corexa Pharmacy (www.CorexaRx.com/store), has begun direct-to-consumer (DTC) distribution of Tollovid®, a 3CL protease inhibitor dietary supplement, and Galactovid™, a medical food for the dietary management of galectin-1 and galectin-3 associated viral infections,
Tollovid and Galactovid are marketed by Tollo Health, LLC ("Tollo Health"), a healthcare company focused on the commercialization of nutraceuticals that address specific mechanisms of action and health IT support tools to maximize patient outcomes. Corexa Health is DataMEDS' pharmacy-focused wholly-owned subsidiary. Corexa Health has entered into a pharmacy-focused distribution arrangement with Tollo Health to make its products available through its pharmacist-supported channels and through its own Corexa Pharmacy subsidiary. DataMeds AI has separately entered into a letter of intent to acquire a controlling interest in Tollo Health, a transaction that remains subject to the negotiation of definitive agreements and customary closing conditions. There can be no assurance that it will be completed on the terms currently contemplated, or at all.
"Long COVID is a devastating physical condition that has upended the lives of tens of millions of patients worldwide, including nearly twenty million patients in the U.S. since the beginning of the pandemic according to the NIH," said Gerald E. Commissiong, Interim Co-CEO of DataMeds AI. "The treatment market for Long COVID is expected to grow from $3.2 billion in 2023 to over $32.8 billion in 2031 according to Clearview Market Insights. We attribute this massive expected growth to the development of new protocols that combine existing biopharmaceutical drugs with supplements and medical foods to help patients manage their symptoms, along with growing awareness of Long COVID and its links to related diagnoses such as Postural Orthostatic Tachycardia Syndrome (POTS), and increasingly available diagnostic tools connecting biomarker patterns to chronic pathogen response."
"We also believe it is crucial to address acute viral infections, and our portfolio of products is expected to make a meaningful impact for patients as awareness grows," Mr. Commissiong added.
Tollovid is a dietary supplement formulated to support healthy immune function, with in vitro data indicating inhibition of 3CL protease activity associated with SARS-CoV-2. Galactovid is a medical food formulated for the dietary management of viral infections associated with galectin-1 and galectin-3 activity. Corexa Health Pharmacy's pharmacists have been trained to help patients make appropriate use of these products, which are available to select pharmacists through Corexa-affiliated distribution channels.
About Tollovid®
Tollovid is an oral dietary supplement made from natural ingredients formulated to support healthy immune function and natural antiviral defense. In vitro functional assays indicate that Tollovid's ingredients bind to the active site of the 3CL protease associated with SARS-CoV-2, consistent with a supportive role following acute COVID-19 infection and in connection with Long COVID. Recommended use varies by intended purpose; consumers should refer to product labeling at www.mytollovid.com for complete usage information.
To purchase Tollovid, please visit www.CorexaRx.com/Store.
About Galactovid™
Galactovid is a medical food for the dietary management of galectin-1 and galectin-3 associated viral infections. Galactovid is formulated to inhibit galectin-1 and galectin-3 proteins, which are associated with the immune response to and cellular entry of various viruses, including SARS-CoV-2, Herpes Simplex Virus-1, and Influenza A. Galactovid's ingredients are Generally Recognized As Safe (GRAS) and may be used alongside other natural antiviral products as part of a broader management plan for acute or chronic viral infections, including those associated with Long COVID.
To purchase Galactovid, please visit www.CorexaRx.com/Store.
About Tollo Health, LLC
Tollo Health, LLC is a healthcare company developing and commercializing nature-based therapeutics, including Tollovid and Galactovid, alongside its Health Lives Here telehealth platform and TolloBio biologics development programs. Corexa Health Pharmacy, a subsidiary of DataMeds AI, Inc., distributes select Tollo Health products under a wholesale distribution arrangement.
About DataMeds AI, Inc.
DataMeds AI, Inc. (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding: the Company's non-binding letter of intent to acquire a controlling interest in Tollo Health, LLC, and the anticipated timing, structure, terms and completion of that transaction; the Company's proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the Company's ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company's technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations.
Forward-looking statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others: the risk that the Company's proposed acquisition of a controlling interest in Tollo Health, LLC may not be completed on the anticipated terms or timeline, or at all, including because the parties have not yet executed definitive agreements; the risk that the proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors may not be completed on the anticipated terms or timeline, or at all; the risk that closing conditions may not be satisfied or waived; risks related to integrating multiple businesses, technologies and platforms; risks related to the development, commercialization, adoption, scalability and regulatory treatment of artificial intelligence, blockchain-enabled data management, telemedicine, pharmacy, laboratory, wearable-device and digital health technologies; risks related to the regulatory classification and marketing claims applicable to dietary supplements and medical foods, including Tollovid and Galactovid; risks related to healthcare privacy, cybersecurity, data ownership, data monetization and compliance with applicable healthcare, pharmacy, consumer protection, data protection and securities laws; risks related to the Company's liquidity, capital resources, indebtedness, dilution, outstanding securities, registration statements and ability to raise additional capital; risks related to maintaining compliance with Nasdaq listing standards; market, regulatory, competitive and operational risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence, technology and digital asset sectors; and other risks described in the Company's filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
DataMeds AI Media Contact
James Lambert, Vice President
Rubenstein Public Relations
Phone: 212.805.3024
Email: [email protected]
Ryder ve 2. čtvrtletí zvýšil EPS o 12,4 % na 3,73 USD a tržby o 5 % na 3,35 miliardy USD. Firma zároveň navýšila celoroční výhled EPS na 14,40 až 14,80 USD z předchozího rozpětí 14,05 až 14,80 USD.
Key Takeaways Ryder's second-quarter EPS rose 12.4% to $3.73 as revenues increased 5% to $3.35 billion.Ryder raised 2026 EPS guidance as fleet earnings improved and first-half free cash flow reached $684 million.Ryder's $7.46 billion debt, limited liquidity and weak momentum profile support a selective stance. Ryder System (R - Free Report) ) has given investors plenty to assess after a sharp 2026 rally and another quarter of earnings growth. Shares are up 39.9% year to date, reflecting better execution and improving used vehicle conditions.
The case is not one-sided. Ryder’s earnings momentum, valuation discount and cash returns support investor interest, but leverage, economic uncertainty and a weaker momentum profile argue for selectivity.
Ryder’s Earnings Beat Strengthens the Bull CaseRyder reported second-quarter 2026 comparable earnings per share of $3.73, up 12.4% year over year. The result exceeded the consensus estimate, with the latest EPS surprise at 0.8%.
Total revenues rose 5% year over year to $3.35 billion. Fleet Management Solutions was a key driver, with earnings before taxes increasing 20% to $150 million on better contractual business performance and improved used vehicle sales.
Management also raised full-year comparable EPS guidance to $14.40-$14.80 from the prior range of $14.05-$14.80. The higher outlook supports the view that Ryder’s contractual portfolio and strategic initiatives are translating into earnings growth.
R Trades Below Key Sales Valuation BenchmarksRyder trades at 0.68X forward 12-month price-to-sales, well below 2.33X for its Zacks sub-industry, 1.45X for the broader transportation sector and 4.97X for the S&P 500.
That discount supports the value argument, especially for investors comparing Ryder with other transportation names. XPO, Inc. (XPO - Free Report) is tied more directly to asset-based less-than-truckload freight transportation, while J.B. Hunt Transport Services, Inc. (JBHT - Free Report) offers a broader freight and logistics model across North America.
Still, Ryder’s own history tempers the valuation case. The stock is also trading at the high end of its five-year price-to-sales range, which has run from 0.28X to 0.68X, with a median of 0.42X.
Ryder’s Cash Returns Reward ShareholdersRyder returned $406 million to shareholders through dividends and buybacks in the first half of 2026. That followed $664 million returned in 2025, $456 million in 2024 and $465 million in 2023.
Since 2021, Ryder has repurchased 26% of its outstanding shares and increased its quarterly dividend by 74%. The latest dividend increase was 11%, marking the fourth straight year of a double-digit raise.
Buybacks can strengthen per-share earnings when supported by durable cash flow. Ryder’s first-half free cash flow rose to $684 million from $461 million a year earlier, giving the company room to reward shareholders while funding fleet replacement and contractual growth.
R’s Debt Burden Limits the UpsideThe balance sheet remains the main offset. Ryder exited the second quarter with $219 million in cash and cash equivalents against $7.46 billion in total debt, including the current portion.
Its current ratio of 0.65 also reflects limited short-term liquidity flexibility. That matters for a capital-intensive leasing model that requires steady investment in vehicles and equipment.
The risk is not immediate distress, but sensitivity. If economic conditions weaken or funding costs stay restrictive, elevated leverage could narrow Ryder’s room to maneuver.
Ryder’s Price Target Leaves Moderate PotentialRyder’s $303 price target compares with the reported share price of $267.68. That implies about 13.2% appreciation potential from that level.
The upside is meaningful, but not overwhelming after the stock’s 39.9% year-to-date gain. Investors are no longer looking at a neglected setup.
Industry positioning also adds caution. Ryder’s industry sits in the bottom 32% of the Zacks Industry Rank, limiting the broader near-term backdrop even as company-specific execution has improved.
R’s Signals Favor Patience Over AggressionThe bottom line: Ryder’s earnings growth, value profile and shareholder returns keep the stock on the radar, but the rally has already priced in part of the improvement.
The stock currently carries a Zacks Rank #3 (Hold), which supports a measured stance rather than an aggressive near-term buying call. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Ryder’s Value Score of A and VGM Score of A strengthen the valuation case. Its Growth Score of B points to improving earnings prospects, while the Momentum Score of D cautions against chasing the stock after its strong advance.
Brisbane, Queensland, Australia--(Newsfile Corp. - July 27, 2026) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that Blackwoods will distribute GMG Products in Australia. Blackwoods will distribute GMG's liquid graphene products: G® LUBRICANT and THERMAL-XR®.
Blackwoods is Australia's leading supplier of industrial and safety solutions, supporting businesses of all sizes across mining, manufacturing, construction, transport, government, utilities and other critical industries. Established in 1878 and part of the Wesfarmers Group (ASX: WES), Blackwoods provides an extensive range of over 300,000 products spanning safety, personal protective equipment, tools, workwear, maintenance, repair and operations supplies, and specialised industrial solutions.
Blackwoods operates a national network of branches, distribution centres and online platforms, supported by more than 2,000 team members and a dedicated field sales force.
John Veitch, Blackwoods Category Manager for Australia, commented "Blackwoods is pleased to add GMG's innovative graphene-enhanced products to our industrial product offering across Australia. Our customers are continually looking for practical solutions that support equipment reliability, operational efficiency and improved asset performance. We see G® LUBRICANT and THERMAL-XR® as strong additions to our range and look forward to supporting their availability through our branch, sales and distribution network."
Craig Nicol, CEO & Managing Director of the Company, commented "We are very pleased to have Blackwoods distribute G® LUBRICANT and THERMAL-XR® in Australia. Blackwoods has an excellent reputation, extensive customer reach and a strong industrial distribution network, making them an ideal channel partner for GMG as we continue to commercialise our graphene-enhanced products. Blackwoods' focus on industrial customers, safety, quality and reliable supply aligns strongly with GMG's approach to bringing practical graphene solutions to market. We believe this relationship can help increase customer access to G® LUBRICANT and THERMAL-XR® across a wide range of industrial and commercial applications."
Jack Perkowski, Non-Executive Chairman and Director of the Company, commented: "This is an important commercial development for GMG. Partnering with a leading industrial distributor such as Blackwoods provides GMG with an established route to market in Australia and supports our strategy of scaling sales through high-quality distribution partners. Blackwoods' extensive branch network, sales capability and customer relationships provide a strong platform for GMG's products. The Board is pleased to see continued progress in building the commercial foundations for GMG's graphene products."
About GMG:
GMG is an Australian based clean-technology company which develops, makes and sells graphene enhanced products manufactured where the graphene is made via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.
The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.
In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.
GMG's 4 critical business objectives are:
Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.
This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding: the anticipated distribution of G® LUBRICANT and THERMAL-XR® by Blackwoods, the potential for Blackwoods to distribute additional GMG products, alignment between Blackwoods and GMG and its impact on bringing GMG's graphene solutions to market, Blackwoods' role in increasing customer access to G® LUBRICANT and THERMAL-XR® across a wide range of industrial and commercial applications, Blackwoods providing GMG with an established route to market in Australia and supporting GMG's scaling strategy, Blackwoods providing a strong platform for GMG products, GMG's intentions to develop commercial scale-up capabilities, GMG's focus in the energy savings segment, GMG's intentions for the use of graphene lubricant additive on saving liquid fuels, expectations for R&D and commercialisation of G+AI Batteries, GMG's ability to improve the performance of lithium-ion batteries and the Company's four critical business objectives.
Such forward-looking statements are based on a number of assumptions of management. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that GMG does not receive or receive on a timely basis the fully signed consent notice from the and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/306628
Source: Graphene Manufacturing Group Ltd.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Ryder System uspořádal konferenční hovor k výsledkům za 2. čtvrtletí 2026. V úvodu zaznělo jen upozornění na prohlášení o výhledu do budoucna a rizika.
Ryder System, Inc. (R) Q2 2026 Earnings Call July 23, 2026 11:00 AM EDT
Company Participants
Calene Candela - Vice President of Investor Relations
John Diez - CEO & Director
Cristina Gallo-Aquino - CFO, EVP & Principal Accounting Officer
John Sensing - President of Global Supply Chain Solutions & Dedicated Transportation Solutions
Tom Havens - President of Global Fleet Management Solutions
Conference Call Participants
Bascome Majors - Stephens Inc., Research Division
Jordan Alliger - Goldman Sachs Group, Inc., Research Division
Robert Salmon - Wells Fargo Securities, LLC, Research Division
Nancy Hipp - Morgan Stanley, Research Division
Harrison Bauer - Susquehanna Financial Group, LLLP, Research Division
Brandon Oglenski - Barclays Bank PLC, Research Division
Jeffrey Kauffman - Citizens JMP Securities, LLC, Research Division
Scott Group - Wolfe Research, LLC
Benjamin Mohr Mok - Citigroup Inc., Research Division
Brian Ossenbeck - JPMorgan Chase & Co, Research Division
Presentation
Operator
Good morning, and welcome to the Ryder System Second Quarter 2026 Earnings Release Conference Call. [Operator Instructions] Today's call is being recorded. If you have any objections, please disconnect at this time. I would now like to introduce Ms. Calene Candela, Vice President, Investor Relations for Ryder. Ms. Candela, you may begin.
Calene Candela
Vice President of Investor Relations
Thank you. Good morning, and welcome to Ryder's Second Quarter 2026 Earnings Conference Call. I'd like to remind you that during this presentation, you'll hear some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to changes in economic, business, competitive, market, political and regulatory factors.
More detailed information about these factors and a reconciliation of each non-GAAP financial measure to the nearest GAAP measure is contained in this morning's earnings release, earnings call presentation
Ryder (R - Free Report) came out with quarterly earnings of $3.73 per share, beating the Zacks Consensus Estimate of $3.7 per share. This compares to earnings of $3.32 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +0.81%. A quarter ago, it was expected that this truck leasing company would post earnings of $2.29 per share when it actually produced earnings of $2.54, delivering a surprise of +10.92%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Ryder, which belongs to the Zacks Transportation - Equipment and Leasing industry, posted revenues of $3.35 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.14%. This compares to year-ago revenues of $3.19 billion. The company has topped consensus revenue estimates just once over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Ryder shares have added about 44.4% since the beginning of the year versus the S&P 500's gain of 9.6%.
What's Next for Ryder?While Ryder has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Ryder was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.23 on $3.36 billion in revenues for the coming quarter and $14.73 on $13.22 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Transportation - Equipment and Leasing is currently in the bottom 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Freightcar America (RAIL - Free Report) , has yet to report results for the quarter ended June 2026.
This rail car maker is expected to post quarterly earnings of $0.01 per share in its upcoming report, which represents a year-over-year change of -90.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Freightcar America's revenues are expected to be $109.92 million, down 7.3% from the year-ago quarter.
Key Takeaways R hiked its quarterly dividend by 10.9% to $1.01 per share, payable on Sept. 18 to shareholders as of Aug. 24.This marks R's 200th consecutive quarterly dividend, continuing over 50 years of uninterrupted payouts.Dividend-paying stocks are less susceptible to market swings and act as a hedge against economic uncertainty. Last week, Ryder System, Inc. (R - Free Report) ) stated that its board of directors had announced an increase in its quarterly dividend payout, reflectingthe company’s commitment to boosting shareholder value, apart from underlining confidence in its business.
Dividend-paying stocks provide a solid income stream and have fewer chances of experiencing wild price swings. Dividend stocks are safe bets for creating wealth, as the payouts generally act as a hedge against economic uncertainty, like the current scenario.
Given this backdrop, the question that naturally arises is: Should investors buy, hold, or sell Ryder stock now? A more in-depth analysis is needed to make that determination. Before diving into Ryder’s investment prospects, let’s take a glance at its financial numbers.
Ryder’s Recent Dividend Increase of 10.9%In a shareholder-friendly move, Ryder’s board of directors has approved a dividend hike of 10.9%, thereby raising its quarterly cash dividend to $1.01 per share ($4.04 annualized) from 91 cents ($3.64 annualized). The raised dividend will be paid on Sept. 18, 2026, to shareholders of record as of the close of business on Aug. 24, 2026. The move reflects R’s intention to utilize free cash to enhance its shareholders’ returns.
R's latest dividend hike is the first increase since July 2025, implying the company’s confidence in its financial footing. This marks Ryder’s 200th consecutive quarterly cash dividend. Notably, Ryder has been making uninterrupted dividend payments for more than 50 years.
Ryder has been making uninterrupted dividend payments for more than 48 years. Ryder’s bottom line has been benefiting from its consistent efforts to reward its shareholders through dividends and share buybacks. During 2022, Ryder paid dividends of $123 million and repurchased shares worth $557 million. In 2023, Ryder paid dividends of $128 million and repurchased shares worth $337 million. In 2024, Ryder returned $456 million in cash to shareholders through share repurchases and dividends. During 2025, Ryder returned $664 million to shareholders through share repurchases and dividend payments. During first-quarter 2026, Ryder returned $272 million to shareholders in the form of share repurchases and dividends.
Apart from being shareholder-friendly, Ryder is well-served by its focus on contractual growth and operational discipline. Upbeat used vehicle sales, particularly in its fleet management segment, along with stable pricing and improved contractual sales activity, bode well.
Ryder's cost-cutting initiatives in response to the weak freight market conditions are also commendable. Higher free cash flow generation expectation (this reflects lower capital spending due to softer lease sales activity) for the full year is another added positive. Ryder generated $2.59 billion of cash from operating activities in 2025, higher than the $2.26 billion generated in 2024. For 2026, adjusted ROE (return on equity) is expected to be in the range of 17-18%. Net cash from operating activities is still projected to be $2.7 billion.
Ryder Stock’s Price PerformanceShares of Ryder have gained 40.5% so far this year, outperforming the Zacks Transportation - Equipment and Leasing industry’s 11.8% increase, as well as that of other industry players, The Greenbrier Companies, Inc. (GBX - Free Report) and Wabtec Corporation (WAB - Free Report) .
Ryder Stock’s YTD Price Comparison Image Source: Zacks Investment Research
Attractive Valuation Picture for Ryder StockRyder looks cheap from a valuation standpoint. Considering the forward 12-month price-to-sales ratio (P/S-F12M), Ryder is trading at a discount compared to the industry.
The stock has a forward 12-month P/S-F12M of 0.76X compared with 2.26X for the industry over the past five years. These factors indicate that the stock’s valuation is attractive. Ryder has a Value Score of A.
Ryder P/S Ratio (Forward 12 Months) Vs. Industry Image Source: Zacks Investment Research
What Do Earnings Estimates Say for Ryder?The positive sentiment surrounding Ryder stock is evident from the fact that the Zacks Consensus Estimate for the third quarter of 2026 and the fourth quarter of 2026 earnings has been revised upward in the past 90 days. The consensus mark for 2026 and 2027 earnings has also been projected northward in the past 90 days.
The favorable estimate revisions indicate brokers’ confidence in the stock.
Image Source: Zacks Investment Research
Time to Buy Ryder StockApart from being attractively valued, Ryder stock is being well-served by its focus on contractual growth and operational discipline. Upbeat used vehicle sales, particularly in its fleet management segment, along with stable pricing and improved contractual sales activity, bode well. Initiatives to reward its shareholders through dividends and buybacks are praiseworthy as well.
We believe that the positives surrounding the stock (as highlighted throughout the write-up) outweigh the concerns regarding supply-chain disruptions and high fuel costs due to the ongoing conflict in the Middle East, tariff-induced economic uncertainties, risks associated with an economic slowdown, geopolitical tensions and a leveraged balance sheet. We, therefore, suggest investors add Ryder stock to their portfolios for healthy returns. The company’s Zacks Rank #2 (Buy) further supports our thesis. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
BioLargo uvádí CupriDyne pro produkty pro domácí mazlíčky pod dosud neoznámenou značkou po úspěchu Pooph, které pod licencí vygenerovaly přes 125 milionů USD v tržbách. Firma začne v oblasti péče o domácí mazlíčky a poté se rozšíří do domácích odor a čisticích produktů.
BioLargo's newly formed subsidiary, BioLargo CPG, will bring to consumers the authentic, independently safety-tested CupriDyne® technology under its own brand following the marketing success of the original Pooph products that generated more than $125 million in pet-care sales while under license from BioLargo.
WESTMINSTER, CA / ACCESS Newswire / July 13, 2026 / BioLargo, Inc. (OTCQX:BLGO) today announced that it is preparing to relaunch CupriDyne®-based consumer pet products under a yet-to-be-announced brand. Targeting pets first, the new consumer products subsidiary will eventually expand into household odor and cleaning products. Formed to fill the gap left by Pooph's ongoing withdrawal from the market, BioLargo will sell direct to consumers and through online marketplaces such as Amazon, leveraging a "digital-first" strategy that allows for hyper-specific audience targeting, real-time performance tracking, and flexible budgets, rather than depending on expensive television campaigns.
CupriDyne-based pet products generated over $125 million in sales while under license and marketed under the Pooph brand. Unfortunately, a series of business decisions by Pooph's management later culminated in its abandonment of CupriDyne-formulated products, the foreclosure of their assets by their lender, board and CEO resignations, and what appears to be the cessation of business operations. BioLargo always owned the CupriDyne technology and had to revoke Pooph's license. Now, the ownership of the Pooph brand is embroiled in litigation. "As a result, we have an opportunity to leverage the prior marketing success by introducing our own brand" said Joseph Provenzano, who will lead the new BioLargo consumer products subsidiary as CEO.
BioLargo's launch brings the CupriDyne® technology and BioLargo's original products back to consumers who loved them. According to Grand View Research1, the U.S. pet odor control and clean-up products market was valued at approximately $6.47 billion in 2023 and is projected to reach approximately $8.87 billion by 2030. BioLargo's initial launch into pet odor control is part of a much larger home and pet cleaning opportunity. The company views pet care as a proven, well-defined category where the difference between masking and eliminating odors is immediately obvious to consumers. Unlike the Pooph brand, BioLargo's new brand will not be limited to pets, and will use the pet product launch to anchor a broader expansion of CupriDyne products across the home.
BioLargo has assembled a team of branding, marketing, creative, and channel-sales experts with proven track records building and growing consumer brands nationally in the pet and household categories. It plans to release additional information, including the product line, the brand name, and key team members, as the product nears its formal launch.
"It will be great to get back into the pet odor control and consumer products business", said Dennis Calvert, BioLargo CEO. "We have seen what can be done, and this time we will own the brand and control the marketing and distribution."
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
CONTACT:
Investor Relations
Matt Kreps
Darrow Associates, Inc.
214-597-8200 [email protected]
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863 [email protected]
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
1 Grand View Research (2004), U.S. Pet Odor Control & Clean-up Products Market(2024 - 2030) https://www.grandviewresearch.com/industry-analysis/us-pet-odor-control-clean-up-products-market-report
Key Takeaways R hiked its quarterly dividend by 10.9% to $1.01 per share, payable on Sept. 18 to shareholders as of Aug. 24.This marks R's 200th consecutive quarterly dividend, continuing over 50 years of uninterrupted payouts.Dividend-paying stocks are less susceptible to market swings and act as a hedge against economic uncertainty. In a shareholder-friendly move, Ryder System, Inc.’s (R - Free Report) board of directors has approved a dividend hike of 10.9%, thereby raising its quarterly cash dividend to $1.01 per share ($4.04 annualized) from 91 cents ($3.64 annualized). The raised dividend will be paid on Sept. 18, 2026, to shareholders of record as of the close of business on Aug. 24, 2026. The move reflects R’s intention to utilize free cash to enhance its shareholders’ returns.
R's latest dividend hike is the first increase since July 2025, implying the company’s confidence in its financial footing. This marks Ryder’s 200th consecutive quarterly cash dividend. Notably, Ryder has been making uninterrupted dividend payments for more than 50 years.
Shares of Ryder performed well on the bourse on July 9, 2026, closing the trading session at $269.63 per share, up 1.6% from the previous day's closing. The surge comes on the heels of the dividend hike announcement by Ryder’s board of directors, reflecting investor confidence in the stock.
Ryder’s chief executive officer, John Diez, stated, “Our transformed business model continues to outperform prior cycles and has enabled us to increase our quarterly dividend by 74% since 2021. This dividend increase reflects the positive view of Ryder’s long-term outlook, the strength and quality of our cash flows, and our ongoing commitment to our shareholders.”
Ryder has been making uninterrupted dividend payments for more than 48 years. Ryder’s bottom line has been benefiting from its consistent efforts to reward its shareholders through dividends and share buybacks. During 2022, Ryder paid dividends of $123 million and repurchased shares worth $557 million. In 2023, Ryder paid dividends of $128 million and repurchased shares worth $337 million. In 2024, Ryder returned $456 million in cash to shareholders through share repurchases and dividends. During 2025, Ryder returned $664 million to shareholders through share repurchases and dividend payments. During first-quarter 2026, Ryder returned $272 million to shareholders in the form of share repurchases and dividends.
Dividend-paying stocks provide a solid income stream and have fewer chances of experiencing wild price swings. Dividend stocks, like R, are safe bets for creating wealth, as the payouts generally act as a hedge against economic uncertainty, like the current scenario.
R’s management’s decision to increase its quarterly dividend payout reflects the company’s commitment to boosting shareholder value, apart from underlining confidence in its business. We believe such shareholder-friendly initiatives should boost investor confidence and positively impact thisZacks Rank #2 (Buy) company’s bottom line. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Dividend Hike Announced by Other Transportation Companies in 2026Ryder is not the only player from theZacks Transportation sector that has rewarded its shareholders with dividend payouts or share buyback programs in 2026.
To name a few, on June 18, 2026, Delta Air Lines, Inc.’s (DAL - Free Report) board of directors approved a dividend hike of 15%, thereby raising its quarterly cash dividend to 21.50 cents per share (86 cents annualized) from 18.75 cents (75 cents annualized). The raised dividend will be paid on July 30, 2026, to stockholders of record at the close of business on June 9, 2026. The move underscores DAL's strong financial position and robust cash-flow generation, highlighting its commitment to delivering value to shareholders.
On May 5, 2026, Expeditors International of Washington, Inc.’s (EXPD - Free Report) board of directors approved a dividend hike of 5.1%, raising its quarterly semi-annual cash dividend from 77 cents per share to 81 cents. The raised dividend was paid on June 16, 2026, to all its shareholders of record as of June 1. Additionally, in February 2026, EXPD’s board approved a new share repurchase program, which allows the repurchase of up to $3 billion of its shares. Since 2024, EXPD has returned almost $2 billion to shareholders in the form of dividend payments and share repurchases.Such moves reflect EXPD’s intention to utilize free cash to enhance its shareholders’ returns.
On Feb. 04, 2026 (concurrent with its fourth-quarter 2025 earnings release), Old Dominion Freight Line, Inc. (ODFL - Free Report) board of directors approved a dividend hike of 3.6%, thereby raising its quarterly cash dividend to 29 cents per share ($1.16 annualized) from 28 cents ($1.12 annualized). The raised dividend was paid on March 18, 2026, to shareholders of record at the close of business on March 4. The move reflects ODFL’s intention to utilize free cash to enhance its shareholders’ returns.
